Interim Results from the Phase 1B and Phase 2 TORREY Open-label Extension Study of Seralutinib in Pulmonary Arterial Hypertension (PAH) - Ghofrani, H; Sahay, S; Escribano-Subias, P; Zolty, R; Kingrey, J; Penn, B; Sobol, I; Sood, N; Benza, R; Channick, R; Chin, K; Frantz, R; Hemnes, A; Howard, L; McLaughlin, V; Vachiéry, J; Zamanian, R; Cravets, M; Roscigno, R; Mottola, D; Parsley, E; Aranda, R; Zisman, L; Sitbon, O (Pneumologie, 2025)